Lilly, Insitro Ink Unique AI Deal, Eye Novel Treatments for Metabolic Diseases

In a departure from most deals, startup insitro will in-license Lilly’s delivery technology for its investigational liver-targeted siRNA therapies. The pharma will be eligible for milestones and royalties down the line.